| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3209503 | Journal of the American Academy of Dermatology | 2007 | 4 Pages |
Abstract
Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Jacob A. Sepmeyer, John P. Greer, Tatsuki Koyama, John A. Zic,